# Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

> **NCT00357994** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 36 (actual)

## Conditions studied

- Advanced Parkinson's Disease

## Interventions

- **DRUG:** Levodopa carbidopa intestinal gel (LCIG)
- **DRUG:** Placebo gel
- **DRUG:** Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
- **DRUG:** Placebo (PBO) oral capsules
- **DEVICE:** CADD-Legacy® 1400 ambulatory infusion pump
- **DEVICE:** PEG tube
- **DEVICE:** J-tube

## Key facts

- **NCT ID:** NCT00357994
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357994, "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00357994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*